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Abstract
Background: A paradoxical immunologic response (PIR) to Highly Active Antiretroviral Therapy (HAART), defined as
viral suppression without CD4 cell-count improvement, has been reported in the literature as 8 to 42%, around
15% in most instances. The present study aims to determine, in a cohort of HIV infected patients in Brazil, what
factors were independently associated with such a discordant response to HAART.
Methods: A case-control study (1:4) matched by gender was conducted among 934 HIV infected patients on
HAART in Brazil. Cases: patients with PIR, defined as CD4 < 350 cells/mm
3 (hazard ratio for AIDS or death of at least
8.5) and undetectable HIV viral load on HAART for at least one year. Controls: similar to cases, but with CD4 counts
≥ 350 cells/mm
3. Eligibility criteria were applied. Data were collected from medical records using a standardized
form. Variables were introduced in a hierarchical logistic regression model if a p-value < 0.1 was determined in a
bivariate analysis.
Results: Among 934 patients, 39 cases and 160 controls were consecutively selected. Factors associated with PIR in
the logistic regression model were: total time in use of HAART (OR 0.981; CI 95%: 0.96-0.99), nadir CD4-count (OR
0.985; CI 95%: 0.97-0.99), and time of undetectable HIV viral load (OR 0.969; CI 95%: 0.94-0.99).
Conclusions: PIR seems to be related to a delay in the management of immunodeficient patients, as shown by its
negative association with nadir CD4-count. Strategies should be implemented to avoid such a delay and improve
the adherence to HAART as a way to implement concordant responses.
Background
Highly active antiretroviral therapy (HAART) has been
introduced in the therapeutic arsenal for HIV infection
since the 90’s. The efficacy of HAART turned HIV
infection into a chronic condition which made it possi-
ble to considerably improve its survival rate over the
last 20 years [1-3]. Such an improvement was in conse-
quence of the virologic suppression that occurs in
approximately 70% of patients during the first regimen
of HAART [4], thus making their immunologic reconsti-
tution possible [1,5].
The frequency of a paradoxical immunologic response
to HAART, defined as viral suppression without CD4
cell-count improvement, has been reported in the litera-
ture as 8 to 42%, around 15% in most instances [6-25].
Several outcomes have been related to this poor
immunologic response. Most of the studies had demon-
strated worse outcomes when compared to those with
complete response such as the increased risk of AIDS-
defining illness or death [14,16,23,25]. Some authors,
however, did not observe statistically significant differ-
ences between these outcomes in full responders and
non-immunologic responders [26,27].
The efforts to determine the prevalence of this condi-
tion and its associated factors are hampered by the
absence of standardization in its definitions. Different
studies establish different boundaries in the CD4 cell
counts or different time frames to cross such boundaries
in the characterization of an adequate immune response,
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[6,8,10,14,16,22,28].
Different associated factors have also been pointed out
by several authors, like older age [7,10,12,18,20,22,
28-35], lower [19,20,23,24,32,34-37] or higher
[10,18,21,28,38-40] baseline CD4 cell count, lower nadir
CD4 count [20,22]; poor adherence to HAART [10,41];
regimen of HAART [10,31,32,38,42]; levels of baseline
viral load [8,10,12,15,18,21-23,28,32,33,36] and even
comorbidities [20,43] and HIV transmission category
[6,8,28,34].
The present study aims to determine, in a cohort of
HIV infected patients in Brazil, what factors were inde-
pendently associated with such a discordant response to
HAART.
Methods
Study Population and Design
Study individuals were selected from a cohort of 934
patients under treatment with HAART in a specialized
facility in the city of Vitória, Espírito Santo State, Brazil.
The study was designed as a matched case-control
approach. Each case was matched to four controls on
gender. Retrospective analysis was performed by a single
investigator who collected the data from charts using a
standardized form containing demographic, socioeco-
nomic, and clinical and laboratory variables.
Cases were all patients with paradoxical immunologic
response (PIR) being defined as a CD4 cell count below
350 cells/mm
3 in a patient with viral load suppressed
who was on HAART over a year in the moment of the
sampling. Controls were patients with the same charac-
teristics as described for the cases, except for a CD4
count greater than or equal to 350 cells/mm
3.
This level of CD4 was used because hazard ratios as
high as 10.7 were found for AIDS or death when com-
paring individuals with counts below 200 cells/mm
3
with those with counts above 350 cells/mm
3. Even com-
parison with individuals with counts between 200 and
350 cells/mm
3 revealed a hazard ratio as high as 8.5
[44]. Regarding viral suppression, the limit of detection
most often used over the past years was 400 copies/ml,
whereas in the study period (April-September 2009) the
limit was 50 copies/ml.
The controls were consecutively selected from the
total number of patients who met the matching criteria
from cases. As cases and controls were defined by the
level of CD4 cell count, such count should be consis-
tently determined by a constant value measured at least
for twice during the previous six months (April-Septem-
ber 2009). For the purpose of this study, previous year
was that between Oct. 1, 2008 and Sept. 30, 2009.
Sample size was calculated assuming an 80% power
for the test, a 95% confidence interval in the estimation
of the effect, a minimum frequency among controls of
25% for any of the assessed risk factors, a ratio of one
case to four controls and a frequency of the risk factors
three times higher in the group of cases. With these
parameters, 30 cases and 120 controls were necessary to
discriminate the difference estimated a priori. This cal-
culation was conducted using Epi Info™ Version 3.5.1.
This study was approved by local Institutional Com-
mittee of Ethics on research on Sept. 9, 2009 under the
registration number 087/09. Data collection was per-
formed from Oct. 1, 2009 to Jan. 31, 2010.
Eligibility Criteria
Inclusion criteria were: age greater or equal to 18 years
old; having started HAART according to Brazilian
guidelines, with CD4 < 350 cell/mm
3;u s eo fH A A R T
for more than one year at inclusion; at least two CD4
counts in the previous six months; HIV viral load < 400
copies/ml (most common limit of laboratory detection
over time) during six months before inclusion, and to
be registered at the local outpatient clinic.
Individuals were excluded if they: had participated in
the programmed interruption of HAART at any time
during their follow-up; underwent treatment with inter-
feron or chemotherapy in the last year; were considered
as immune failures in the previous year (defined as a
decline of more than 25% of the CD4 count); were con-
sidered as clinical failures in the previous year (defined
as the occurrence or recurrence of AIDS defining illness
after 3 months of HAART); had irregular use of
HAART in the previous year (defined as discontinuation
of the regimen for more than 30 consecutive days);
failed to attend the medical appointments in the pre-
vious 6 months, and were pregnant at the inclusion
moment of the sampling process.
Statistical analysis
Chi-square test or Fisher’s exact test were used for com-
parison of categorical variables between the two groups.
For continuous variables, “Student’s” T test was used for
comparison of normal distributions between the two
groups. For non-normal distributions, it was used the
Mann-Whitney test.
Multivariate analysis was performed by the binary
logistic regression model using Enter method for all
variables with a p-value < 0.1 in the bivariate analysis
model. It is important to note that the inclusion of vari-
ables in this model was performed according to a hier-
archical causal theoretical tree previously developed for
this study. Such a hierarchy had previous application in
epidemiological studies to improve the accuracy of sta-
tistical analysis [45].
The model was fitted with the selected variables that
fulfilled the requirements for logistic regression: being
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having values in the cells of the cross tabs greater than
or equal to one, and having not more than 20% of cells
values below five. Variables were not included in the
model if missing information exceeded 10% of the
sample.
The independency among variables was tested to see if
there was a correlation or association between them.
Pearson correlation test or Chi-square test was per-
formed, as more appropriate. When variables were asso-
ciated or correlated with each other, the one chosen to
enter the model was the most significant in the bivariate
analysis or the most relevant in clinical practice.
The Hosmer-Lemeshow test was used to verify if the
variables were well adapted to the theoretical model.
All statistical analyses were performed through the
SPSS software (SPSS Statistics package version 15.0).
Ethical Clearance
The study protocol was approved by the Ethics Comitee
of the Center of Health Sciences of the Universidade
Federal do Espírito Santo.
Results
Out of 934 patients on HAART during the study period
(April-September 2009) 563 had undetectable HIV viral
load (HIVVL) (limit of detection: 50 copies/ml). Out of
563 with viral suppression, 39 cases and 160 controls
were consecutively selected, with individual matching by
gender. Controls were derived from 272 medical records
sequentially verified. In the group of cases, there were
eight females and 31 males, whereas in the control
group 36 females and 124 males.
Sampling of cases and controls according to the elig-
ibility criteria of the study is represented in Figure 1.
Descriptive and bivariate analyses
Demographic and socioeconomic characteristics of the
199 patients (39 cases and 160 controls) included in the
study are shown in Table 1.
The median age at diagnosis for AIDS and the onset
of the first HAART regimen was 38 years old. From
these subjects (cases plus controls) 37.3% were single,
44% married, 11% separated, and 7.7% widowed. Regard-
ing race/color, there were 47.1% of white people, 38.1%
mixed, and 14.8% black. The educational level of the
patients was as follows: 19.7% had four years of educa-
tion at most; 40.4% had up to eight years; 29.5% had
completed high school, and 8.7% with University educa-
tion (completed or not).
There was no statistically significant difference
between groups for the following clinical data: HIV
transmission category; Rio de Janeiro/Caracas or Centers
of Diseases Control (CDC) adapted criteria for AIDS
definition; comorbidities in the previous year; the year
of HIV diagnosis; time from HIV diagnosis until the
beginning of the first HAART (Table 2). AIDS diagnosis
was based mainly on adapted CDC criteria (88.4% of
reports), and 70% of AIDS cases reported had determi-
nation of less than 350 CD4 cells/mm
3. Regarding the
HIV transmission category, 97% of them had a sus-
pected sexual exposure, 11.2% were injecting drug users,
and only 0.5% was related to a blood transfusion (Table
2).
Cases and controls differed in the presence or not of
an AIDS defining illness before their first HAART regi-
men (p-value = 0.040); in the presence or not of an
AIDS defining illness before any HAART (p = 0.04); if
they had been using concomitant medication in the pre-
vious year for over thirty consecutive days (p = 0.002);
in the total time in use of HAART in months (p =
0.001), and in time of use of current HAART in months
(p < 0.001) (Table 2).
Regarding the components of the HAART regimen,
cases and controls differed in the presence or not of
Zidovudine (p = 0.021), and had a marginal difference
in their frequency resulting from the association of
nucleoside analogues reverse transcriptase inhibitors
with non-nucleoside analogues (p = 0.099). There were
no significant differences for the following variables:
therapy containing tenofovir plus didanosine; regimen
containing protease inhibitors; prior use of mono or
dual antiretroviral therapy; occurrence of substitutions
in the components of HAART since the first regimen in
use; number of substitutions since the first HAART
regimen in use; percentage of visits attended in the last
year, and the percentage of absences in the pharmaceu-
ticals dispensations in the last year (data not shown).
Differences were observed in the presence of comor-
bidities and in the frequency of concomitant medica-
t i o n sa sf o l l o w s :p r e s e n c eo fd y s l i p i d e m i ai nt h e
previous year (p = 0.002, OR 0.226, 95% CI 0.083 to
0.613), use of fibrates (p = 0.006, OR 5.306, 95% IC
1.477 to 19.057), and prophylaxis with trimethoprim-sul-
famethoxazole (p < 0.001, OR 0.026, 95% CI 0.007 to
0.103) (data not shown).
There were also differences in the reasons for HAART
substitutions: prior abandonment or poor adherence (p
= 0.018, OR 3.392, 95% CI 1.33 to 8.65), and Zidovudine
myelotoxicity (p = 0.001, OR 23.3, 95% CI 2.64 to
206.59) (data not shown).
Regarding laboratorial data, the following are the dif-
ferent characteristics between cases and controls: lym-
phopenia before first HAART (p = 0.026) and before
the current HAART (p = 0.007), CD4 count prior to
the first HAART (p = 0.001) and before the current
HAART (p < 0.001), nadir CD4 count (the lowest
CD4-count ever presented by patient during outpatient
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Page 3 of 11follow-up) (p < 0.001), time of undetectable HIVVL (p
< 0.001) and time of HIVVL below 1 000 copies/ml (p
< 0.001). There were no statistically significant differ-
ences between the two groups regarding the HIV viral
loads before the first HAART and before the current
HAART, either in absolute numbers or in logarithm
values (Table 3).
Logistic Regression Analysis
Figure 2 presents the final hierarchical theoretical model
used for multivariate analysis of the results.
Variables that remained significantly different after
logistic regression were: total time in use of HAART
(adjusted OR 0.981; CI 95%: 0.96-0.99), nadir CD4-
count (adjusted OR 0.985; CI 95%: 0.97-0.99) and time
of undetectable HIVVL (adjusted OR 0.969: CI 95%:
0.94-0.99) (Table 4).
For total time in use of HAART, the odds ratio for
each additional month was 0.981, i.e., for each additional
month of ART use there is a reduction of 1.9% in the
risk for paradoxical immune response (PIR). For each
additional month of undetectable HIVVL there is a
reduction of 3.1% in the risk of PIR (Table 4).
Regarding nadir CD4-count, every increase of one cell
corresponded to a reduction of 1.5% in the risk of PIR
(Table 4). Otherwise, each increase of 100 cells/mm
3 in
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE. HAART, Highly Active Antiretroviral Therapy; HIVVL, HIV viral load; CD4, CD4 
Lymphocyte Count.  CD4 are expressed in cells/mm
3. 
563 with HIVVL undetectable (<50copies/ml) 
39 CASES                
(8 females and 31 males) 
107 patients with CD4 < 350 cells/mm
3 
2 clinic non –attendance 
for at least 6 months 
934 patients on HAART (from April to September 2009) 
13 without CD4 pre-HAART 
2 used  interferon 
2 patients were on Home 
Care Assistance 
1 without HAART at least 30 
consecutive days in the last year 
456 patients with CD4  350 cells/mm
3 
19 only one CD4 < 350 
28 were on HAART less than 
one year 
1 began HAART with CD4 > 350 
272 medical records 
sequentially verified 
184  records  
not verified 
160 CONTROLS             
(36 females and 124 males) 
39 without CD4 pre-HAART  
21 only one CD4  350 
19 on HAART for less than 1 year 
2 without HAART for at least 30 days 
19 began HAART with CD4 > 350 
3 used interferon 
5 were previously on programmed 
interruption of HAART  
2 pregnant 
1 clinic non –attendance for at 
least 6 months 
Figure 1 Flow Chart of Eligibility Criteria.
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of 77.7%.
Discussion
Paradoxical Immune Response (PIR) has been sur-
rounded by uncertainties, both regarding its determinant
factors and its consequences for the outcome of HIV
infection. Despite its retrospective design and use of
preexisting data, this study was able to uncover a nega-
tive association between PIR and total time in use of
HAART as well as time for undetectable HIV viral load.
Such an association was not adequately revealed by
other studies because of their rigid eligibility criteria in
terms of time frames, thus preventing any analysis of
the influence of time frames on the outcomes
[6,12,16,19-21,23].
Time of HIVVL suppression can be a surrogate mar-
ker of adherence to HAART. Thus, patients who have
good adherence and, therefore, a longer time of unde-
tectable HIVVL are less likely to come forward with
paradoxical immune response. Such an association has
also been reported by others [10,41]. Long time in use
of HAART increases chances of optimal immune
response. Several studies regarding this subject used pre-
determined goals to be met in terms of CD4-count. As
an example, in the cohort study by Florence et al (2003)
[20], it was considered adequate the immune response
gain of ≥ 50 CD4-cells/mm3 or ≥ 75 cells/mm3 versus
use of HAART for six (6) months or twelve (12)
months, respectively. Dronda et al (2002) [6] considered
adequate the immune response elevation of 100 cells/
mm3 or higher at 24 months of HAART whereas for
Kaufmann et al (2005) [23] the ideal immune response
to be achieved after five years of ART was an elevation
of 500 CD4 cells/mm3 or higher.
Another variable independently associated with PIR in
this study was the nadir CD4-count. In other studies,
both baseline CD4-count (measured before starting
HAART) [10,18-21,23,24,28,32,34-40,46] and nadir
CD4-count [20,22,37,47] have been associated with para-
doxical immune response. As nadir CD4-count and
baseline CD4-count are correlated, the present study
Table 1 Demographic and socioeconomic characteristics among cases and controls.
Demographic and socioeconomic
characteristics
Cases (n = 39
a) Controls (n = 160
a) Bivariate
analysis
p-value
c
AGE AT AIDS DIAGNOSIS
b (years) 42.4 ± 14.3 Median: 38 (IQR: 32.7-
49.5)
40,2 ± 10.9 Median: 38.50 (IQR: 31.5-
48.7)
0.637
AGE AT HAART INITIATION
b 42,8 ± 10 Median: 38 (IQR: 32.7-49.5) 40,54 ± 10.8 Median: 39 (IQR: 31.5-48.7) 0.630
RACE/SKIN COLOR - n (%) 0.440
White 14 (35.9) 75 (46.9)
Mixed 17 (43.6) 55 (34.4)
Black 6 (15.4) 22 (13.8)
MARITAL STATUS - n (%) 0.989
Single 13 (33.3) 55 (34.4)
Married 14 (35.9) 66 (41.2)
Separate/divorced 3 (7.7) 17 (10.6)
Widow 2 (5.1) 12 (7.5)
OCCUPATION - n (%) 0,258
Unemployed 2 (5.1) 6 (3.7)
Not specialized 8 (20.2) 52 (32.5)
Autonomous 7 (18) 12 (7.5)
Specialized 2 (5.1) 7 (4.3)
Others 19 (25.6) 80 (50)
EDUCATION - n (%) 0,656
Four years at most 6 (15.4) 33 (20.6)
Until eight years 18 (46.1) 56 (35)
High school 11 (28.2) 43 (30.6)
Universitary education 2 (5.1) 14 (8.7)
n, number; HAART, highly active antiretroviral therapy.
a different values due to missing data.
b Continuous data presented by mean ± standard deviation (SD) and by median with interquartile range (IQR).
c Chi-square test or Fisher’s exact test were used for comparison of categorical variables between the two groups, as more appropriate. For continuous variables,
“Student’s” T test was used for comparison of normal distributions between the two groups. For non-normal distributions, it was used the Mann-Whitney test.
Casotti et al. BMC Infectious Diseases 2011, 11:306
http://www.biomedcentral.com/1471-2334/11/306
Page 5 of 11Table 2 Clinical characteristics among cases and controls.
Clinical characteristics Cases (n = 39
a)
n (%)
Controls
(n = 160
a)
n (%)
Bivariate analyses
p-
value
e
OR CI 95%
HIV transmission by intravenous drug use 1.00 0.88 0.28-2.7
Yes 4 (10.2) 18 (11.5)
No 35 (89.8) 139 (86.6)
AIDS defining illness before HAART 0.04
b 2.34 1.0-5.3
Yes 11 (28.2) 23 (14.4)
No 28 (71.8) 137 (85.6)
AIDS defined by Rio de Janeiro/Caracas criteria 0.53 1.38 0.49-
3.85
Yes 5 (12.8) 27 (16.8)
No 34 (87.2) 133 (83.1)
AIDS defined by CDC adapted criteria 0.40 1.52 0.56-
4.17
Yes 33 (84.6) 143 (89.3)
No 6 (15.4) 17 (10.6)
Comorbidities in the previous year 0.43 0.75 0.36-
1.54
Yes 24 (61.5) 109 (68.1)
No 15 (38.4) 51 (31.9)
Irregular use of HAART in the previous year 0.07
c 2.22 0.9-5.3
Yes 9 (23.1) 19 (11.9)
No 30 (76.4) 141 (88.1)
Concomitant medication in the previous year for more than 30
consecutive days
0.00
b 0.29 0.1-0.6
Yes 30 (76.9) 79 (49.3)
No 9 (23.1) 81 (50.7)
Year of HIV diagnosis 0.32 1.99 0.64-
6.11
Before 1996 5 (12.8) 11 (6.9)
After 1996 34 (87.2) 149 (93.1)
Year of AIDS diagnosis 0.09
c 8.59 0.75-
97.3
Before 1996 2 (5.1) 1 (0.6)
After 1996 37 (94.8) 159 (99.4)
Time from HIV diagnosis until first HAART (months)
d 39.6 ± 52.2 12.8 ± 26.9 0.57
Median: 19.5 (IQR: 1.7-
63)
Median: 5.5 (IQR: 2.2-
10.7)
Total time in use of HAART (months)
d 36.1 ± 39,7 62.0 ± 32,5 0.00
b
Median: 17 (IQR: 13.7-
53.5)
Median: 60 (IQR: 33.2-
96)
Time in use of last HAART regimen (months)
d 19.2 ± 18.3 44.2 ± 28.6 0.00
b
Median: 15 (IQR: 12.2-
15.2)
Median: 37 (IQR: 19.2-
70.2)
n, number; OR, odds ratio; CI 95%, confidence interval of 95%; HAART, highly active antiretroviral therapy; CDC, Centers for Disease Control and Prevention.
a different totals are due to missing data.
b p-value < 0,050.
c p-value < 0,1; variables that could be included in multivariate analysis.
d Continuous data are represented by mean ± standard deviation and by median with interquartile range (IQR).
e Chi-square test or Fisher’s exact test were used for comparison of categorical variables between the two groups, as more appropriate. For continuous variables,
“Student’s” T test was used for comparison of normal distributions between the two groups. For non-normal distributions, it was used the Mann-Whitney test.
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because it represents the lowest CD4 count value ever
observed in a patient, along with his/her medical history,
thus representing in fact the worst immune status he/
she had ever had. The finding of an association between
the increase in cell count at nadir CD4 determination
and a decreasing risk of PIR conforms to Florence et al
(2003) [20], Kaufmann et al (2002) [22] and Zoufaly et
al (2010) [47] studies data.
Studies have been undertaken to elucidate the
mechanisms involved in the occurrence of this poor
immune response. Some of these studies have found
direct association between the frequency of paradoxical
immune response and the increase in T-cell activation
(or persistence) and, consequently, excessive apoptosis
of these cells [4,48,49]. Brenchley et al (2006) [50]
observed that the bacterial translocation in these
patients on HAART was the causation for the activation
of their immune system.
Other studies have reported a relationship between
PIR and cytokines profile. As an example, Sachdeva et al
(2008) [36] demonstrated a low capacity to produce
interferon alpha in patients with paradoxical immune
response. Other authors have found associations with a
reduced performance of interleukin 7 (IL-7) in the body,
which was probably due to a down regulation of its
receptor (CD127) during HIV infection [51]. Based on
these conclusions, Levy et al (2009) [52] conducted a
phase I/II clinical trial using IL-7 in patients with PIR,
and demonstrated that this cytokine induced for a
higher increase of CD4 cells when compared to that
observed in the placebo group. A positive effect was also
observed in the functional activity of CD4 cells in the
group receiving IL-7 [52].
Table 3 Laboratorial characteristics among cases and controls.
Cases (n = 39
a) Controls (n = 160
a) Bivariate analysis
Laboratorial characteristics n (%) n (%) p-
value
c
OR CI
95%
Lymphopenia prior to first HAART 0.026
b 2.6 1.0-
6.5
Yes
No
10 (25.6)
19 (48.7)
22 (13.7)
112 (70)
Lymphopenia prior to current HAART 0.007
b 3.4 1.3-
8.8
Yes
No
10 (25.6)
18 (46.1)
16 (10)
100 (62.5)
CD4-count prior to the first HAART
d
(cells/mm
3)
119.2 ± 104.5 Median: 82.5 (IQR: 19-215) 189.1 ± 87.4 Median: 206
(IQR: 122.7-47.7)
0.001
b
HIVVL prior to first HAART
d (copies/ml) 96 251 ± 110 029 Median: 54 193 (IQR:
33 250-117 647)
263 711 ± 501 872 Median: 104 192 (IQR:
19 766-330 500)
0.294
Logarithm of HIVVL prior to the use of
the first HAART
d
4.7 ± 0.4 Median: 4.7 (IQR: 4.5-5) 5 ± 0.7
Median: 5.1
(IQR: 4.3-5.5)
0.547
CD4-count prior to the current HAART
d
(cells/mm
3)
125.2 ± 109.4 Median: 119 (IQR: 19-190) 288.2 ± 237.5 Median: 225 (IQR: 164-321) 0.000
b
HIVVL prior to the current HAART
d
(copies/ml)
90 725 ± 114 158 Median: 54 192 (IQR: 9
360-117 647)
125 178 ± 168 825 Median: 47 800 (IQR:
16 413-205 773)
0.487
Logarithm of HIVVL prior to the current
HAART
d
4.4 ± 0.9 Median: 4.7
(IQR: 3.9-5)
4.6 ± 1
Median: 4.8
(IQR: 4.2-5.4)
0.842
Nadir CD4-count
d (cells/mm3) 85.3 ± 68.1 Median: 80.5 (IQR: 19-127.2) 177.8 ± 87.8 Median: 202
(IQR: 109.5-239.5)
0.000
b
Time of undetectable HIVVL
d (months) 9.2 ± 4.2 Median: 9.5 (IQR: 5-12.2) 28.8 ± 21.3
Median: 26.5
(IQR: 12.7-35.7)
0.000
b
Time of HIVVL below 1,000 copies/ml
d
(months)
18.8 ± 20.3 Median: 12 (IQR: 8-20.2) 38.9 ± 25.2 Median: 28
(IQR: 22.2-65.2)
0.000
b
n, number; OR, odds ratio; CI 95%, confidence interval of 95%; HAART, highly active antiretroviral therapy; CD4, CD4 Lymphocyte Count; HIVVL, HIV viral load;
Nadir CD4-count, the lowest CD4 ever presented by patient; Undetectable HIVVL, over time the most common limit of detection was less than 400 copies/ml.
a different totals are due to missing data.
b p-value < 0,050.
c Chi-square test or Fisher’s exact test were used for comparison of categorical variables between the two groups, as more appropriate. For continuous variables,
“Student’s” T test was used for comparison of normal distributions between the two groups. For non-normal distributions, it was used the Mann-Whitney test.
d Continuous data are represented by mean ± standard deviation and by median with interquartile range (IQR).
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by studies highlighting a correlation with thymus size and
function [7,10,12,18,21,22,28,29,31-34]. In the present
study, age had not the importance evidenced by others.
Recent guidelines for the treatment of HIV infection
do not establish a rigid CD4 cell count threshold at
which therapy should be initiated. The International
AIDS Society-USA Panel, for example, states that
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Figure 2 Hierarchical causal theoretical model for data insertion in the multivariate analysis.
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Page 8 of 11deciding when to initiate HAART is mainly a matter of
the readiness of the patient [1]. Such recommendations
are based on evidence that the benefits of treatment
outweigh any additional risk posed by anti-retroviral
drugs, as a long-standing untreated viremia implies a
chronic inflammatory state resulting in end-organ
damage and comorbid conditions. According to the lit-
erature, life expectancy in individuals with HIV infection
i sr e d u c e de v e na th i g h e rC D 4cell counts [53]. Conse-
quently, there is a concern to tailor the initiation of
therapy according to other events related to HIV repli-
cation apart from CD4 cell-count limits, such as indica-
tions of rapid progression, older age and comorbid
conditions [1]. Although the basic criteria in the present
study are related to CD4 count as a determining factor
for treatment, the results support the conclusion that
early therapy could improve the immune response, as
demonstrated by the inverse relationship between nadir
CD4 count and the occurrence of PIR.
The limitations of the present study are those inherent
to the case-control design, particularly regarding the
vulnerability to selection bias and misclassification. Such
possibilities are even more evident when one considers
the preexistence of the data and the selection of preva-
lent cases. However, the consistence of the associations
observed between the candidate variables of exposure
and the outcome reinforces the validity of the conclu-
sions, even if some potential risk factors could have per-
sisted undetected.
Conclusions
The main contribution of this study lies in the demon-
stration of an independent association of PIR with mar-
kers of intense immunossupression such as low nadir
CD4 counts and short periods of time for undetectable
viral loads. It seems that immune reconstitution is a
process that depends on a residual immune function to
be effective. In other words, if the immunossupression
had gone too far, it could be too late to obtain a consis-
tent reconstitution.
Therefore, there is a need for more studies, mainly
with a prospective design to fully establish the conse-
quences of PIR. If there is an important impact over
morbidity and quality of life, as anticipated, the conclu-
sions from studies like this one should strengthen the
need for early intervention with HIV infected patients
regarding HAART. The more we learn about it, the
more we understand the complex nature of HIV infec-
tion, and better strategies are made available to allow
for safe and effective intervention for the immune
reconstitution. In the future, inadequate responses like
PIR should be eliminated at the best scenario.
Table 4 Logistic Regression Results.
Characteristics Univariate analysis Multivariate analysis
b
p-value OR CI 95% p-value Aj OR CI 95%
Total time in use of HAART 0.000
a - - 0.013
a 0.981 0.96-0.99
Concomitant medications over 30 consecutive days in previous year 0.002
a 0.109
Yes --
No 0.29 0.13-0.65 0.423 0.14-1.21
Modifications in HAART before previous year due to abandonment or poor adherence 0.018
a 0.159
No --
Yes 3.39 1.33-8.65 2.852 0.66-12.25
Regimen containing zidovudine 0.021
a 0.359
Yes --
No 2.28 1.11-4.66 1.601 0.58-4.37
AIDS defining illness prior to HAART 0.040
a 0.515
Yes 0.88 0.28-2.77 1.475 0.45-4.74
No --
Irregular use of HAART in previous year 0.071
a 0.403
Yes 2.22 0.91-5.39 1.888 0.42-8.36
No --
Nadir CD4-count 0.000
a - - 0.000
a 0.985 0.97-0.99
Time of undetectable HIVVL 0.000
a - - 0.037
a 0.969 0.94-0.99
OR, odds ratio; CI 95%, confidence interval of 95%; Aj OR, adjusted odds ratio; HAART, highly active antiretroviral therapy; nadir CD4-count, the lowest CD4 ever
presented by patient; HIVVL, HIV viral load; undetectable HIVVL, over time the most common limit of detection was less than 400 copies/ml.
a p-value < 0,050.
b Multivariate analysis was performed by the binary logistic regression model using Enter method for all variables with a p-value < 0.1 in the bivariate analysis
model who fitted the requirements for logistic regression. It is important to note that the inclusion of variables in this model was performed according to a
hierarchical causal theoretical tree previously developed for this study.
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